The effectiveness of TMZ is modulated by the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT), where the epigenetic silencing of MGMT serves as a favorable prognostic marker, correlating with extended survival and delayed progression in GBM patients [11]. Here, MGMT is linked to glioblastoma.